Cherevka Holli 4
4 · Ampio Pharmaceuticals, Inc. · Filed Apr 29, 2021
Insider Transaction Report
Form 4
Cherevka Holli
Chief Operating Officer
Transactions
- Exercise/Conversion
Common Stock
2021-04-27$0.51/sh+30,000$15,300→ 30,000 total - Exercise/Conversion
Common Stock
2021-04-27$0.51/sh+44,631$22,762→ 74,631 total - Exercise/Conversion
Stock Option (Right to Buy)
2021-04-27$0.51/sh−30,000$15,300→ 0 totalExercise: $0.51Exp: 2027-08-08→ Common Stock (30,000 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2021-04-27$0.51/sh−44,631$22,762→ 155,369 totalExercise: $0.51Exp: 2029-09-16→ Common Stock (44,631 underlying) - Sale
Common Stock
2021-04-27$2.00/sh−74,631$149,262→ 0 total
Footnotes (4)
- [F1]The option exercise reported on this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on March 12, 2021.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.00 to $2.005, inclusive. The reporting person undertakes to provide to Ampio Pharmaceuticals, Inc., any security holder of Ampio Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
- [F3]Options were granted and previously reported on a Form 4 filed on September 21, 2017, where all of the options reported vested and became exercisable immediately.
- [F4]Options were granted and previously reported on a Form 4 filed on September 18, 2019, where 50% of the options awarded vested and became exercisable on the grant date of September 16, 2019 and the other 50% of the options awarded vested and became exercisable on the first anniversary of the grant date.